Yahoo India Web Search

Search results

1. alexion.comAlexion

   alexion.com

   • Cached

   Alexion is a global biopharmaceutical company that develops therapies for rare and devastating diseases. It is part of AstraZeneca, a leading healthcare company with a focus on innovation and value creation.

   • Career Opportunities

     Life at Alexion: Being Part Of AstraZeneca. In July 2021,...

   • Research and Development

     Alexion is committed to collaborating with researchers on...

   • Our Inspiration

     Living With Rare Diseases. Rare diseases can be devastating...

   • Our Medicines

     New Haven, CT: Alexion Pharmaceuticals, Inc; 2015. Tonsgard...

   • Our Commitment

     Our work contributes to AstraZeneca’s commitment to...

   • Our Company

     At Alexion, our passion drives us to continuously innovate...

   • News & Media

     Alexion, AstraZeneca Rare Disease is focused on serving...

   • Contact Us

     Contact Us. In order to direct your inquiry to the correct...

2. Videos

   • 

     2:06

     youtube.com

     Alexion, AstraZeneca Rare Disease: Who We Are

     2 Aug 2024

   • 

     1:32

     youtube.com

     Life At Alexion: Being Part of AstraZeneca

     3 May 2022

     2K views

   • 

     2:49

     bloomberg.com

     AstraZeneca to Buy Alexion in $39 Billion Deal

     12 Dec 2020

   View all

3. www.astrazeneca.com › media-centre › press-releasesAcquisition of Alexion completed - AstraZeneca

   www.astrazeneca.com › media-centre › press-releases

   • Cached

   Jul 21, 2021 · AstraZeneca announces the closing of the deal to buy Alexion, a biopharmaceutical company focused on rare diseases, for $13.3bn. The acquisition enhances AstraZeneca's presence in immunology and complement-biology, and expands its global footprint and pipeline.

4. www.astrazeneca.com › media-centre › press-releasesAstraZeneca to acquire Alexion, accelerating the Company's ...

   www.astrazeneca.com › media-centre › press-releases

   • Cached

   Dec 12, 2020 · AstraZeneca and Alexion have entered into a definitive agreement for AstraZeneca to acquire Alexion for $39bn. The acquisition will enhance AstraZeneca's presence in immunology and rare diseases, and create a company with great strengths across a range of technology platforms.

5. Images

   • 
   • 
   • 

   View all

6. www.astrazeneca.com › media-centre › press-releasesAlexion, AstraZeneca Rare Disease, enters agreement with ...

   www.astrazeneca.com › media-centre › press-releases

   • Cached

   Jul 28, 2023 · The agreement aims to advance genomic medicines for rare diseases with novel AAV capsids and technologies. Alexion, AstraZeneca Rare Disease, will pay up to $1bn and royalties to Pfizer for the assets.

7. www.ft.com › content › a7444fd3/0044/4aab-ab23-60eb7AstraZeneca to buy Alexion in $39bn immunology deal

   www.ft.com › content › a7444fd3/0044/4aab-ab23-60eb7

   Dec 12, 2020 · Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the...

8. www.nytimes.com › astrazeneca-alexion-dealAstraZeneca to Buy Alexion for $39 Billion - The New York Times

   www.nytimes.com › astrazeneca-alexion-deal

   Dec 12, 2020 · LONDON — The drug maker AstraZeneca agreed on Saturday to buy Alexion, a biopharmaceutical company, for $39 billion in cash and stock, as corporate giants resume big-ticket takeovers, even amid...

9. People also ask

   What does AstraZeneca do?

   • AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

   Acquisition of Alexion completed - AstraZeneca

   www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html

   See all results for this question

   What is AstraZeneca doing with Alexion?

   • AstraZeneca now has an enhanced scientific presence in immunology and, through Alexion’s innovative complement-biology platform and robust pipeline, will continue to pioneer the discovery and development of medicines for patients with rare diseases.

   Acquisition of Alexion completed - AstraZeneca

   www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html

   See all results for this question

   What does Alexion's announcement mean for AstraZeneca?

   • Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease, said: “Today’s announcement represents another major step forward in Alexion and AstraZeneca’s ambition to be an industry leader in genomic medicine, which has potential to be transformative and even curative for patients with devastating diseases.

   Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to

   www.astrazeneca.com/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer.html

   See all results for this question

   Will Alexion help AstraZeneca expand in immunology?

   • The deal for Alexion will help AstraZeneca expand in another sector: immunology, where treatments can be highly lucrative for their makers. Alexion, which is based in Boston, is known for focusing on combating rare diseases: Its top drugs include Soliris and Ultomiris, which treat blood disorders.

   AstraZeneca to Buy Alexion for $39 Billion - The New York Times

   www.nytimes.com/2020/12/12/business/dealbook/astrazeneca-alexion-deal.html

   See all results for this question

10. www.nasdaq.com › press-release › alexionAlexion Shareholders Approve Acquisition by AstraZeneca

    www.nasdaq.com › press-release › alexion

    • Cached

    May 11, 2021 · As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH)...